Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

RV1MAG-26K

Millipore

MILLIPLEX® Rat Vascular Injury Magnetic Bead Panel 1 - Toxicity Multiplex Assay

The analytes available for this multiplex kit are: Caveolin-1, CINC-1/GRO/KC, CTGF (Connective Tissue Growth Factor), IL-6, MCP-1, PAI-1 (total), TIMP-1, TNFα, VEGF.

Synonyme(s) :

Luminex® Rat Vascular Injury Panel, Millipore Rat Vascualr Injury Panel, Rat Vascular Injury Multiplex Assay

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Code UNSPSC :
12161503
eCl@ss :
32161000
Nomenclature NACRES :
NA.84

Niveau de qualité

200

Espèces réactives

rat

Fabricant/nom de marque

Milliplex®

assay range

accuracy: 97-108%
intra-assay cv: <10%
standard curve range: 0.1-100 ng/mL
(CINC-1/GRO/KC, IL-6, MCP-1, PAI-1 (total))
standard curve range: 0.1-15 ng/mL
(VEGF)
standard curve range: 0.1-20 ng/mL
(TNFα)
standard curve range: 0.2-150 ng/mL
(TIMP-1)
standard curve range: 0.3-200 ng/mL
(CTGF)
standard curve range: 1.4-1,000 ng/mL
(Caveolin-1)
inter-assay cv: <10%
(All other analytes)
inter-assay cv: <15%
(CINC-1/GRO/KC, PAI-1 (total), TIMP-1, TNFα)
inter-assay cv: <20%
(Caveolin-1)

Technique(s)

multiplexing: suitable

Méthode de détection

fluorometric (Luminex xMAP)

Conditions d'expédition

wet ice

Description générale

Vascular injury is important to address during the preclinical safety study of drugs. A lack of well-defined mechanisms of drug-induced vascular injury (DIVI) in animals, and the absence of specific, qualified biomarkers have become significant barriers in the development of new therapeutic treatments. In the past, hemodynamics, such as heart rate and mean arterial blood pressure, were used to measure DIVI risks but these only targeted single biomarkers. Today, some of the known vascular injury mechanisms are related to vascular wall shear and/or circumferential “hoop” stress, drug/chemical toxicity, and immunological mediation. With these known biomechanics, primary targets (smooth muscle, endothelial and immune-mediated cells) yield a number of promising candidate biomarkers for DIVI study. We provide valuable research assays to investigate multiple biomarkers of vascular injury in rat serum and plasma samples using the Luminex® xMAP® instrument platform.

The MILLIPLEX® Rat Vascular Injury Bead Panel contains all the components necessary to measure the following 9 biomarkers in any combination using Luminex® xMAP® technology: Caveolin-1, CINC-1/GRO/KC, CTGF (Connective Tissue Growth Factor), IL-6, MCP-1, PAI-1 (total), TIMP-1, TNFα, VEGF. The kit uses a 96-well format, contains a lyophilized standard cocktail, 2 quality controls and can measure up to 38 serum or plasma samples in duplicate.

Panel Type: Toxicity

Spécificité

There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

Application

  • Analytes: Caveolin-1, CINC-1/GRO/KC, CTGF (Connective Tissue Growth Factor), IL-6, MCP-1, PAI-1 (total), TIMP-1, TNF-α, VEGF
  • Recommended Sample type: serum and plasma
  • Recommended Sample dilution: 1:4 in kit Serum Matrix
  • Assay Run Time: Overnight
  • Research Category: Toxicity

Caractéristiques et avantages

Design your multiplex kit by choosing available analytes within this panel.

Conditionnement

Everything you need in a single kit.

Stockage et stabilité

Recommended storage for kit components is 2 - 8°C.

Autres remarques

Please contact Technical Service for linearity of dilution.
Sensitivity: See kit protocol for individual analytes sensitivities.

Informations légales

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organes cibles

Respiratory Tract

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Philipp Baumann et al.
American journal of translational research, 14(1), 343-354 (2022-02-18)
Intensive care practice calls for ventilator adjustments due to fast-changing clinical conditions in ventilated critically ill children. These adaptations include positive end-expiratory pressure (PEEP), fraction of inspired oxygen (FiO2), and respiratory rate (RR). It is unclear which alterations in ventilator
Philipp Baumann et al.
Physiological reports, 6(2) (2018-01-31)
Mechanical ventilation (MV) is routinely used in pediatric general anesthesia and critical care, but may adversely affect the cardiocirculatory system. Biomarkers are increasingly measured to assess cardiovascular status and improve clinical treatment decision-making. As the impact of mechanical ventilation strategies
Evandro M Neto-Neves et al.
The American journal of pathology, 187(4), 700-712 (2017-02-12)
Our understanding of the pathophysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an animal model that replicates the phenotype of human CTEPH. Sprague-Dawley rats were administered a combination of a single dose each of plastic microspheres
Mary F Barbe et al.
Journal of musculoskeletal & neuronal interactions, 19(4), 396-411 (2019-12-04)
Fibrosis is one contributing factor in motor dysfunction and discomfort in patients with overuse musculoskeletal disorders. We pharmacologically targeted the primary receptor for Substance P, neurokinin-1, using a specific antagonist (NK1RA) in a rat model of overuse with the goal
Fabrice Antigny et al.
Circulation, 133(14), 1371-1385 (2016-02-26)
Mutations in the KCNK3 gene have been identified in some patients suffering from heritable pulmonary arterial hypertension (PAH). KCNK3 encodes an outward rectifier K(+) channel, and each identified mutation leads to a loss of function. However, the pathophysiological role of

Contenu apparenté

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique